View From ICAAC: How Higher Prices Can Help Save Antibiotic R&D

At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.

SAN FRANCISCO – The future business model for antibiotic drug development should feature higher-priced products with limited access to smaller patient populations, a shift bolstered by regulatory reform in the U.S. and Europe, said experts at the Interscience Conference on Antimicrobial Agents and Chemotherapy meeting.

Very few drug classes actually cure disease as antibiotics do and yet pricing is very low, especially compared to other...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Swissmedic Launches Pilot To Expedite Clinical Trial Applications

 

Swiss health care products agency Swissmedic will launch a pilot in July to fast track clinical trial applications, which the agency claims will place Switzerland at the forefront compared to other European countries.

No ‘Doomsday’ For US Pharma Despite Political Uncertainties, EU Industry Chief Says

 

While challenges in the US present an “incredible opportunity” for Europe, there is no “doomsday” happening there, Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says.

EU Countries Rally Behind Novel Pathway For Combined Drug/IVD Trials

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.